ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TVGN vs LENZ // NET PROFIT MARGIN

Tevogen Inc. (NASDAQ) VS. LENZ Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TVGN 1 — LENZ 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TVGN VS. LENZ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TVGN LENZ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 96.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -27.80% -7.20 LENZ /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -13.02% — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin ACTIVE — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 2.19 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 3/9 -2.00 LENZ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.1 35.8 +1.30 TVGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $92.8M $95.8M -$3.0M LENZ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TVGN REV LENZ REV TVGN GROSS % LENZ GROSS % TVGN FCF LENZ FCF
FY 2025 $73.2M $19.1M — 97.8% -$12.4M -$70.0M
FY 2024 $150.0M $164.1M — — -$12.0M -$59.9M
FY 2023 $24.8M $202.8M — — -$8.2M -$60.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TVGN // BETA —
LENZ // BETA —